Application 214275

Type
NDA
Sponsor
ACTELION

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001UPTRAVISELEXIPAGTABLET;ORAL200MCGNoNo
002UPTRAVISELEXIPAGTABLET;ORAL400MCGNoNo
003UPTRAVISELEXIPAGTABLET;ORAL600MCGNoNo
004UPTRAVISELEXIPAGTABLET;ORAL800MCGNoNo
005UPTRAVISELEXIPAGTABLET;ORAL1000MCGNoNo
006UPTRAVISELEXIPAGTABLET;ORAL1200MCGNoNo
007UPTRAVISELEXIPAGTABLET;ORAL1400MCGNoNo
008UPTRAVISELEXIPAGTABLET;ORAL1600MCGNoNo
009UPTRAVISELEXIPAGINJECTABLE;INJECTION1800MCGNoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
82595-000UPTRAVISELEXIPAGEUROFINS AMATSIGROUP SASNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
69131ORIG2021-10-27
68260ORIG2021-08-02
68248ORIG2021-08-02